Personalis (PSNL) AI Stock Analysis

• Market Cap: $687.35M
• Dividend Yield: N/A
• Average Volume (3M): 1.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: -21.02%
• EPS Growth: 47.74%
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.24
• Shares Outstanding: 88,804,350
• 10 Day Avg. Volume: 1,424,488
• 30 Day Avg. Volume: 1,643,648
• PEG Ratio: 0.11
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 4.05
• P/FCF Ratio: -7.33
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 6.80
• Enterprise Value/Gross Profit: 25.49
• Enterprise Value/Ebitda: -7.38
• 1Y Price Target: $11.00
• Price Target Upside: 38.89% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -0.94
• Revenue Forecast (FY): $70.35M

• Rating: 58 Neutral
• Price Target: $10.00 ▲(26.26% Upside)

Personalis' overall stock score is primarily impacted by its financial challenges, including declining revenue and negative profitability. However, positive technical indicators and strategic advancements in clinical adoption and reimbursement provide some optimism. The company's strong cash position and recent corporate developments further support its potential for recovery and growth.

Positive Factors

Clinical Adoption

Strong clinical adoption of NeXT Personal test indicates robust demand and market acceptance, positioning Personalis well in the precision medicine space.

Medicare Coverage

Medicare coverage for NeXT Personal test enhances market accessibility and could drive increased utilization and revenue in cancer diagnostics.

Cash Position

A strong cash position provides financial stability and flexibility to invest in growth initiatives and withstand market fluctuations.

Negative Factors

Revenue Decline

Significant revenue decline reflects challenges in maintaining sales momentum, potentially impacting long-term financial health and strategic initiatives.

Profitability Challenges

Ongoing profitability issues highlight inefficiencies and may limit the company's ability to reinvest in growth and innovation.

Gross Margin Decrease

Declining gross margins indicate rising costs and pricing pressures, which could affect long-term profitability and competitive positioning.

Personalis Business Overview & Revenue Model

Company Description

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

How the Company Makes Money

Personalis generates revenue primarily through its genomic sequencing services, which are offered to pharmaceutical companies, academic institutions, and healthcare providers. Key revenue streams include fees for sequencing services, data analysis, and partnerships with biopharmaceutical companies for precision medicine applications. The company often collaborates with these partners on clinical trials and drug development programs, providing them with valuable genomic insights that can lead to tailored therapies. Additionally, Personalis may receive funding through grants and research contracts, which support its innovation in genomic technologies.

Personalis Financial Statement Overview

Summary

Personalis faces significant financial challenges, with declining revenue, negative profitability, and cash flow issues. While the company maintains a strong equity position, it struggles with efficiency and profitability, as reflected in negative margins and ROE. Improvements in revenue growth and operational efficiency are crucial for financial stability and growth.

Income Statement

Personalis has faced declining revenue growth, with a negative growth rate of -13.96% in the TTM period. The company struggles with profitability, as evidenced by negative net profit margins (-135.30%) and EBIT margins (-95.49%). The gross profit margin is low at 7.20%, indicating challenges in covering operating expenses. Overall, the income statement reflects significant financial challenges and declining performance.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.19, indicating manageable leverage. However, the return on equity is negative at -38.25%, reflecting poor profitability and efficiency in using equity capital. The equity ratio stands at 70.60%, suggesting a strong equity base relative to total assets. Despite a solid equity position, the negative ROE highlights ongoing profitability issues.

Cash Flow

Personalis has a negative operating cash flow, with a coverage ratio of -1.67, indicating insufficient cash generation to cover net income. The free cash flow growth rate is positive at 34.53%, but the free cash flow to net income ratio of 1.09 suggests reliance on external financing. Overall, cash flow challenges persist, with improvements needed in operational cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	69.10M	84.61M	73.48M	65.05M	85.49M	78.65M
Gross Profit	18.43M	26.82M	18.21M	13.35M	31.66M	20.11M
EBITDA	-63.66M	-70.30M	-96.81M	-104.64M	-59.01M	-35.46M
Net Income	-73.88M	-81.28M	-108.30M	-113.31M	-65.23M	-41.28M
Balance Sheet
Total Assets	242.84M	270.27M	225.10M	292.70M	396.53M	244.84M
Cash, Cash Equivalents and Short-Term Investments	150.51M	185.01M	114.18M	167.66M	287.06M	203.29M
Total Debt	41.87M	44.25M	47.73M	48.65M	58.33M	10.99M
Total Liabilities	71.42M	67.31M	95.66M	74.56M	86.23M	49.90M
Stockholders Equity	171.41M	202.96M	129.44M	218.14M	310.30M	194.94M
Cash Flow
Free Cash Flow	-66.17M	-46.75M	-67.17M	-120.13M	-81.91M	-45.90M
Operating Cash Flow	-60.50M	-45.15M	-56.26M	-70.23M	-70.83M	-42.65M
Investing Cash Flow	-34.37M	-35.07M	13.10M	52.54M	-60.07M	-65.14M
Financing Cash Flow	69.04M	114.67M	11.03M	1.37M	169.70M	121.27M

Personalis Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 7.92
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSNL, the sentiment is Neutral. The current price of 7.92 is below the 20-day moving average (MA) of 9.46, below the 50-day MA of 8.98, and above the 200-day MA of 6.06, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 40.16 is Neutral, neither overbought nor oversold. The STOCH value of 4.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PSNL.

Personalis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$1.00B	16.09	24.11%	―	14.46%	―
CSTL	63 Neutral	$1.16B	―	-2.69%	―	10.15%	-295.52%
PSNL	58 Neutral	$687.35M	-9.05	-43.69%	―	-21.02%	47.74%
FLGT	57 Neutral	$850.09M	-20.02	-3.80%	―	13.60%	74.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LAB	47 Neutral	$596.08M	-4.91	-24.63%	―	-17.37%	52.28%
MYGN	41 Neutral	$647.84M	-1.55	-72.52%	―	0.21%	-233.51%

Personalis Corporate Events

Personalis Announces $100M Stock Offering Amendment

On November 28, 2025, Personalis, Inc. announced a prospectus supplement for the offer and sale of up to $100 million of its common stock. This move is part of an amended sales agreement with Piper Sandler & Co. and BTIG, LLC, and adds to a previous offering under a registration statement.

Personalis Sees Revised Reimbursement Rates for Cancer Tests

On November 24, 2025, the Centers for Medicare & Medicaid Services revised its reimbursement rates for Personalis‘ ultrasensitive NeXT Personal® test, which is used for post-treatment cancer recurrence surveillance in stage II and III breast cancer patients. Effective December 1, 2025, the reimbursement rate for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test will be $4,266, and for the NeXT Personal Single Plasma Test, it will be $1,164, impacting the company’s operations by potentially increasing accessibility and utilization of these tests.

Personalis Gains Medicare Coverage for Cancer Test

Personalis has announced that its NeXT Personal® test, designed for post-treatment surveillance of cancer recurrence, has received Medicare coverage for patients with stage II and III breast cancer. The coverage, effective retroactively from October 7, 2025, includes reimbursement rates for the NeXT Personal Dx Breast MRD Recurrence Monitoring Test and the NeXT Personal Single Plasma Test, potentially enhancing the company’s market position in cancer diagnostics.